NO304010B1 - FremgangsmÕte for fremstilling av en pelletformulering for bruk i behandlingen av inflammatoriske tarmsykdommer - Google Patents

FremgangsmÕte for fremstilling av en pelletformulering for bruk i behandlingen av inflammatoriske tarmsykdommer Download PDF

Info

Publication number: NO304010B1
Authority: NO; Norway
Prior art keywords: budesonide; water; epimer; polymer; insoluble
Prior art date: 1989-11-22

Application number

NO922004A

Other languages

English (en)

Norwegian (no)

Other versions

NO922004L (no

NO922004D0 (no

Inventor

Jan Ulmius

Original Assignee

Draco Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-11-22

Filing date

1992-05-21

Publication date

1998-10-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20377544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO304010(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-05-21 Application filed by Draco Ab filed Critical Draco Ab

1992-05-21 Publication of NO922004L publication Critical patent/NO922004L/no

1992-05-21 Publication of NO922004D0 publication Critical patent/NO922004D0/no

1998-10-12 Publication of NO304010B1 publication Critical patent/NO304010B1/no

Links

238000000034 method Methods 0.000 title claims abstract description 35
238000011282 treatment Methods 0.000 title claims abstract description 29
239000000203 mixture Substances 0.000 title claims description 38
239000008188 pellet Substances 0.000 title claims description 33
238000009472 formulation Methods 0.000 title claims description 23
208000022559 Inflammatory bowel disease Diseases 0.000 title claims description 6
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims abstract description 78
229960004436 budesonide Drugs 0.000 claims abstract description 78
210000000813 small intestine Anatomy 0.000 claims abstract description 10
229920003176 water-insoluble polymer Polymers 0.000 claims description 26
229920000642 polymer Polymers 0.000 claims description 24
230000000968 intestinal effect Effects 0.000 claims description 21
235000011389 fruit/vegetable juice Nutrition 0.000 claims description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
201000010099 disease Diseases 0.000 claims description 14
230000000694 effects Effects 0.000 claims description 12
210000004051 gastric juice Anatomy 0.000 claims description 12
125000000129 anionic group Chemical group 0.000 claims description 10
229920003169 water-soluble polymer Polymers 0.000 claims description 10
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 9
239000012528 membrane Substances 0.000 claims description 9
229920002301 cellulose acetate Polymers 0.000 claims description 6
239000004014 plasticizer Substances 0.000 claims description 6
239000001856 Ethyl cellulose Substances 0.000 claims description 5
230000000181 anti-adherent effect Effects 0.000 claims description 5
229920001249 ethyl cellulose Polymers 0.000 claims description 5
235000019325 ethyl cellulose Nutrition 0.000 claims description 5
239000000463 material Substances 0.000 claims description 5
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
210000002429 large intestine Anatomy 0.000 claims description 4
125000005397 methacrylic acid ester group Chemical group 0.000 claims description 4
239000004094 surface-active agent Substances 0.000 claims description 4
239000005038 ethylene vinyl acetate Substances 0.000 claims description 3
210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
229920002689 polyvinyl acetate Polymers 0.000 claims description 3
239000011118 polyvinyl acetate Substances 0.000 claims description 3
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 2
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 2
238000001727 in vivo Methods 0.000 claims description 2
229920000609 methyl cellulose Polymers 0.000 claims description 2
239000001923 methylcellulose Substances 0.000 claims description 2
235000010981 methylcellulose Nutrition 0.000 claims description 2
229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 2
125000005591 trimellitate group Chemical group 0.000 claims description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
239000000853 adhesive Substances 0.000 claims 1
238000013270 controlled release Methods 0.000 claims 1
206010009900 Colitis ulcerative Diseases 0.000 abstract description 19
201000006704 Ulcerative Colitis Diseases 0.000 abstract description 19
208000011231 Crohn disease Diseases 0.000 abstract description 17
230000001684 chronic effect Effects 0.000 abstract description 5
208000014997 Crohn colitis Diseases 0.000 abstract description 3
238000002560 therapeutic procedure Methods 0.000 abstract description 3
238000010521 absorption reaction Methods 0.000 description 21
210000004027 cell Anatomy 0.000 description 13
239000006185 dispersion Substances 0.000 description 10
238000002835 absorbance Methods 0.000 description 8
238000007922 dissolution test Methods 0.000 description 8
210000001072 colon Anatomy 0.000 description 7
229940079593 drug Drugs 0.000 description 6
239000003814 drug Substances 0.000 description 6
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 6
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
229940068968 polysorbate 80 Drugs 0.000 description 6
229920000053 polysorbate 80 Polymers 0.000 description 6
230000009885 systemic effect Effects 0.000 description 6
QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 5
239000012530 fluid Substances 0.000 description 5
239000007903 gelatin capsule Substances 0.000 description 5
210000000936 intestine Anatomy 0.000 description 5
238000009115 maintenance therapy Methods 0.000 description 5
235000000346 sugar Nutrition 0.000 description 5
239000000454 talc Substances 0.000 description 5
229910052623 talc Inorganic materials 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
231100000987 absorbed dose Toxicity 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
238000001647 drug administration Methods 0.000 description 4
239000002702 enteric coating Substances 0.000 description 4
238000009505 enteric coating Methods 0.000 description 4
239000003862 glucocorticoid Substances 0.000 description 4
239000012729 immediate-release (IR) formulation Substances 0.000 description 4
238000004811 liquid chromatography Methods 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
241000792859 Enema Species 0.000 description 3
229920003135 Eudragit® L 100-55 Polymers 0.000 description 3
229920003163 Eudragit® NE 30 D Polymers 0.000 description 3
229920003141 Eudragit® S 100 Polymers 0.000 description 3
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 3
206010036774 Proctitis Diseases 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
239000007920 enema Substances 0.000 description 3
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
150000003431 steroids Chemical class 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 3
229960001940 sulfasalazine Drugs 0.000 description 3
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 3
206010012735 Diarrhoea Diseases 0.000 description 2
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
208000037976 chronic inflammation Diseases 0.000 description 2
208000037893 chronic inflammatory disorder Diseases 0.000 description 2
238000012321 colectomy Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
229940079360 enema for constipation Drugs 0.000 description 2
230000010224 hepatic metabolism Effects 0.000 description 2
210000003405 ileum Anatomy 0.000 description 2
208000028774 intestinal disease Diseases 0.000 description 2
229960005205 prednisolone Drugs 0.000 description 2
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
229960004618 prednisone Drugs 0.000 description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical group C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 2
239000013589 supplement Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
239000001069 triethyl citrate Substances 0.000 description 2
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
235000013769 triethyl citrate Nutrition 0.000 description 2
208000034577 Benign intracranial hypertension Diseases 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
229920003136 Eudragit® L polymer Polymers 0.000 description 1
229920003153 Eudragit® NE polymer Polymers 0.000 description 1
229920003151 Eudragit® RL polymer Polymers 0.000 description 1
229920003152 Eudragit® RS polymer Polymers 0.000 description 1
229920003137 Eudragit® S polymer Polymers 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229920006243 acrylic copolymer Polymers 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
-1 anti-adhesives Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000002518 antifoaming agent Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
229940094157 budesonide enema Drugs 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940095399 enema Drugs 0.000 description 1
FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
229920006158 high molecular weight polymer Polymers 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000011418 maintenance treatment Methods 0.000 description 1
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
229960004963 mesalazine Drugs 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
239000002184 metal Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000004200 microcrystalline wax Substances 0.000 description 1
235000019808 microcrystalline wax Nutrition 0.000 description 1
DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
150000003022 phthalic acids Chemical class 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229960002800 prednisolone acetate Drugs 0.000 description 1
230000002265 prevention Effects 0.000 description 1
208000001381 pseudotumor cerebri Diseases 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
208000014964 small bowel Crohn disease Diseases 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
229960002211 sulfapyridine Drugs 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Ultra Sonic Daignosis Equipment (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Cosmetics (AREA)
Medicines Containing Plant Substances (AREA)

NO922004A 1989-11-22 1992-05-21 FremgangsmÕte for fremstilling av en pelletformulering for bruk i behandlingen av inflammatoriske tarmsykdommer NO304010B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE8903914A SE8903914D0 (sv)	1989-11-22	1989-11-22	Oral composition for the treatment of inflammatory bowel diseases
PCT/SE1990/000738 WO1991007172A1 (en)	1989-11-22	1990-11-15	Oral composition for the treatment of inflammatory bowel diseases

Publications (3)

Publication Number	Publication Date
NO922004L NO922004L (no)	1992-05-21
NO922004D0 NO922004D0 (no)	1992-05-21
NO304010B1 true NO304010B1 (no)	1998-10-12

Family

ID=20377544

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO922004A NO304010B1 (no)	1989-11-22	1992-05-21	FremgangsmÕte for fremstilling av en pelletformulering for bruk i behandlingen av inflammatoriske tarmsykdommer

Country Status (36)

Country	Link
US (1)	US6423340B1 (de)
EP (1)	EP0502092B1 (de)
JP (1)	JP3145111B2 (de)
KR (1)	KR0179042B1 (de)
AT (1)	ATE125445T1 (de)
AU (1)	AU643021B2 (de)
CA (1)	CA2071518C (de)
DE (1)	DE69021214T2 (de)
DK (1)	DK0502092T3 (de)
EG (1)	EG19642A (de)
ES (1)	ES2074698T3 (de)
FI (2)	FI104949B (de)
GR (1)	GR3017691T3 (de)
HK (1)	HK51897A (de)
HR (1)	HRP920632B1 (de)
HU (2)	HUT60630A (de)
IE (1)	IE74854B1 (de)
IL (1)	IL96415A (de)
IS (1)	IS1858B (de)
LT (1)	LT3696B (de)
LV (1)	LV10183B (de)
MY (1)	MY104535A (de)
NO (1)	NO304010B1 (de)
NZ (1)	NZ235807A (de)
PL (1)	PL166506B1 (de)
PT (1)	PT95946A (de)
RU (1)	RU2134104C1 (de)
SA (1)	SA90110123B1 (de)
SE (1)	SE8903914D0 (de)
SG (1)	SG54210A1 (de)
SI (1)	SI9012150A (de)
TW (1)	TW250435B (de)
UA (1)	UA37196C2 (de)
WO (1)	WO1991007172A1 (de)
YU (1)	YU48583B (de)
ZA (1)	ZA908777B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5316772A (en) *	1990-12-19	1994-05-31	Solvay & Cie, S.A. (Societe Anonyme)	Bilayered oral pharmaceutical composition with pH dependent release
ATE183192T1 (de) *	1993-01-08	1999-08-15	Astra Ab	Neue colon-oder ilean-spezifische steroid derivate
US5914132A (en) *	1993-02-26	1999-06-22	The Procter & Gamble Company	Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE4332394A1 (de) *	1993-09-23	1995-03-30	Falk Pharma Gmbh	Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5686106A (en) *	1995-05-17	1997-11-11	The Procter & Gamble Company	Pharmaceutical dosage form for colonic delivery
KR20000053327A (ko) *	1996-11-15	2000-08-25	데이비드 엠 모이어	결장내 운반에 사용되는 약학적 제형
SE9604751D0 (sv)	1996-12-20	1996-12-20	Astra Ab	New therapy
DE19732903A1 (de)	1997-07-30	1999-02-04	Falk Pharma Gmbh	Pellet-Formulierung zur Behandlung des Intestinaltraktes
US6239120B1 (en)	1998-03-17	2001-05-29	Pharmalink Ab	Method and means for treating glomerulonephritis
GB9824604D0 (en)	1998-11-11	1999-01-06	Hewlett Healthcare Limited	Treatment of allergic conditions
SE9902673D0 (sv) *	1999-07-12	1999-07-12	Astra Ab	New composition
JP2005508836A (ja) *	2001-03-15	2005-04-07	エンテロンファーマシューティカルズインコーポレーティッド	局所作用性コルチコステロイドを用いる胃腸管の炎症性疾患の治療方法
DE10250543A1 (de) *	2002-10-29	2004-05-19	Röhm GmbH & Co. KG	Mehrschichtige Arzneiform
ES2312844T3 (es)	2002-12-12	2009-03-01	Nycomed Gmbh	Medicamento de combinacion de r, r-formoterol y ciclesonida.
WO2004087109A1 (ja) *	2003-03-27	2004-10-14	Hisamitsu Pharmaceutical Co., Inc.	大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
US20060211668A1 (en) *	2003-09-15	2006-09-21	Altana Pharma Ag	Use of ciclesonide for the treatment of inflammatory bowel diseases
JP5618452B2 (ja)	2003-09-16	2014-11-05	タケダゲゼルシャフトミットベシュレンクテルハフツングＴａｋｅｄａＧｍｂＨ	呼吸器疾患の治療のためのシクレソニドの使用
AU2005264864B2 (en)	2004-06-16	2011-08-11	Takeda Pharmaceutical Company Limited	Multiple PPI dosage form
WO2007056539A2 (en) *	2005-11-08	2007-05-18	Medarex, Inc.	Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
CA2684655A1 (en) *	2007-03-26	2008-10-02	Teikoku Seiyaku Co., Ltd.	Oral pharmaceutical preparation for colon-specific delivery
GB0808537D0 (en)	2008-05-12	2008-06-18	Archimedes Dev Ltd	Compositions
WO2010040021A1 (en) *	2008-10-03	2010-04-08	Salix Pharmaceuticals, Ltd.	Compositions and methods for the treatment of bowel diseases with granulated mesalamine
US8945616B2 (en) *	2009-02-17	2015-02-03	Mylan Pharmaceuticals Inc.	Controlled release budesonide minitablets
US8945615B2 (en) *	2009-02-17	2015-02-03	Mylan Pharmaceuticals Inc.	Controlled release budesonide minitablets
AU2012211968A1 (en) *	2011-02-04	2013-08-29	Optimer Pharmaceuticals, Inc.	Treatment of bacterial infections
MD480Z5 (ro) *	2011-07-07	2012-09-30	Эльвира АНДОН	Metodă de tratament al colitei ulceroase nespecifice acute
DK2659881T3 (en)	2012-04-30	2018-02-05	Tillotts Pharma Ag	Delayed release drug formulation
MX2016001840A (es)	2013-10-29	2016-08-11	Tillotts Pharma Ag	Formulacion de farmaco de liberacion retardada.
WO2017042835A1 (en) *	2015-09-11	2017-03-16	Sun Pharmaceutical Industries Ltd.	Oral pharmaceutical dosage forms of budesonide
CN105663091A (zh) *	2016-01-28	2016-06-15	上海信谊百路达药业有限公司	一种布地奈德肠溶缓释胶囊及其制备方法
JP6954926B2 (ja) *	2016-02-09	2021-10-27	アルビレオ・アクチボラグ	経口コレスチラミン製剤及びその使用
RU2750937C2 (ru) *	2016-02-09	2021-07-06	Альбирео Аб	Пероральный состав холестирамина и его применение
EP3613414A1 (de)	2018-08-24	2020-02-26	Dr. Falk Pharma Gmbh	Pellets mit mehrschichtiger struktur zur verzögerten freisetzung des wirkstoffs im distalen kolon
US11896719B2 (en)	2022-01-24	2024-02-13	Calliditas Therapeutics Ab	Pharmaceutical compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3996356A (en)	1969-07-02	1976-12-07	Hoffmann-La Roche Inc.	Composition containing 5-sulfanilamido-3,4-dimethylisoxazole and a trimethoxybenzyl pyrimidine
SE378109B (de)	1972-05-19	1975-08-18	Bofors Ab
SE7813246L (sv)	1978-12-22	1980-06-23	Haessle Ab	Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
FR2471186A1 (fr)	1979-12-10	1981-06-19	Roussel Uclaf	Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
SE8003805L (sv)	1980-05-21	1981-11-22	Haessle Ab	En farmaceutisk beredning med forbettrade utlosningsegenskap
SE8008524L (sv)	1980-12-04	1982-06-05	Draco Ab	4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
ZA825384B (en) *	1981-07-31	1983-05-25	Tillott J B Ltd	Orally administrable pharmaceutical compositions
SE8306370D0 (sv)	1983-11-18	1983-11-18	Draco Ab	Novel androstane-17beta-carboxylic acid esters, a process and intermediates for their preparation, compositions and method for the treatment of inflammatory conditions
US4708867A (en)	1983-12-19	1987-11-24	Key Pharmaceuticals, Inc.	Minipellets
US4606940A (en)	1984-12-21	1986-08-19	The Ohio State University Research Foundation	Small particle formation and encapsulation
DE3536267A1 (de)	1985-10-11	1987-04-16	Bayer Ag	Azofarbstoffe sowie fluessigkristallines material enthaltend azofarbstoffe
SE8506015D0 (sv)	1985-12-19	1985-12-19	Draco Ab	Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives
GB8630913D0 (en) *	1986-12-24	1987-02-04	Glaxo Group Ltd	Pharmaceutical compositions
US4966770A (en)	1989-07-26	1990-10-30	Himedics, Inc.	Prednisone microencapsulated granules
DE10307386A1 (de)	2003-02-21	2004-09-09	Dieter Wildfang Gmbh	Verfahren zum außenseitigen Beschichten eines sanitären Auslaufteiles sowie sanitäres Auslaufteil

1989
- 1989-11-22 SE SE8903914A patent/SE8903914D0/xx unknown
1990
- 1990-10-24 NZ NZ235807A patent/NZ235807A/xx unknown
- 1990-11-01 ZA ZA908777A patent/ZA908777B/xx unknown
- 1990-11-07 TW TW079109396A patent/TW250435B/zh active
- 1990-11-07 SA SA90110123A patent/SA90110123B1/ar unknown
- 1990-11-13 SI SI9012150A patent/SI9012150A/sl unknown
- 1990-11-13 YU YU215090A patent/YU48583B/sh unknown
- 1990-11-15 AT AT91900414T patent/ATE125445T1/de not_active IP Right Cessation
- 1990-11-15 ES ES91900414T patent/ES2074698T3/es not_active Expired - Lifetime
- 1990-11-15 KR KR1019920701202A patent/KR0179042B1/ko not_active IP Right Cessation
- 1990-11-15 UA UA94051483A patent/UA37196C2/uk unknown
- 1990-11-15 RU SU5052239A patent/RU2134104C1/ru active
- 1990-11-15 DE DE69021214T patent/DE69021214T2/de not_active Revoked
- 1990-11-15 SG SG1996004385A patent/SG54210A1/en unknown
- 1990-11-15 CA CA002071518A patent/CA2071518C/en not_active Expired - Lifetime
- 1990-11-15 JP JP50070991A patent/JP3145111B2/ja not_active Expired - Lifetime
- 1990-11-15 EP EP91900414A patent/EP0502092B1/de not_active Revoked
- 1990-11-15 HU HU9201700A patent/HUT60630A/hu unknown
- 1990-11-15 WO PCT/SE1990/000738 patent/WO1991007172A1/en not_active Application Discontinuation
- 1990-11-15 US US09/159,301 patent/US6423340B1/en not_active Expired - Fee Related
- 1990-11-15 AU AU77864/91A patent/AU643021B2/en not_active Expired
- 1990-11-15 HU HU9201700A patent/HU216836B/hu unknown
- 1990-11-15 DK DK91900414.3T patent/DK0502092T3/da active
- 1990-11-20 IL IL9641590A patent/IL96415A/en active IP Right Review Request
- 1990-11-20 EG EG69190A patent/EG19642A/xx active
- 1990-11-20 IE IE417090A patent/IE74854B1/en not_active IP Right Cessation
- 1990-11-20 PL PL90287844A patent/PL166506B1/pl unknown
- 1990-11-21 MY MYPI90002053A patent/MY104535A/en unknown
- 1990-11-21 PT PT95946A patent/PT95946A/pt not_active Application Discontinuation
- 1990-11-21 IS IS3644A patent/IS1858B/is unknown
1992
- 1992-05-21 FI FI922325A patent/FI104949B/fi active
- 1992-05-21 NO NO922004A patent/NO304010B1/no not_active IP Right Cessation
- 1992-09-30 HR HRP-2150/90A patent/HRP920632B1/xx not_active IP Right Cessation
1993
- 1993-08-10 LV LVP-93-1026A patent/LV10183B/en unknown
- 1993-12-31 LT LTIP1751A patent/LT3696B/lt not_active IP Right Cessation
1995
- 1995-10-11 GR GR950402797T patent/GR3017691T3/el unknown
1997
- 1997-04-24 HK HK51897A patent/HK51897A/xx not_active IP Right Cessation
1999
- 1999-09-06 FI FI991893A patent/FI19991893A/fi unknown

Also Published As

Publication number	Publication date
LT3696B (en)	1996-02-26
YU215090A (sr)	1996-01-09
EP0502092B1 (de)	1995-07-26
US6423340B1 (en)	2002-07-23
MY104535A (en)	1994-04-30
GR3017691T3 (en)	1996-01-31
ES2074698T3 (es)	1995-09-16
HRP920632B1 (en)	1999-10-31
FI19991893A (fi)	1999-09-06
SI9012150A (sl)	1998-08-31
AU7786491A (en)	1991-06-13
WO1991007172A1 (en)	1991-05-30
DK0502092T3 (da)	1995-12-27
IS1858B (is)	2003-03-27
CA2071518A1 (en)	1991-05-23
KR920703025A (ko)	1992-12-17
NO922004L (no)	1992-05-21
PT95946A (pt)	1991-09-13
FI104949B (fi)	2000-05-15
LV10183A (lv)	1994-10-20
IE904170A1 (en)	1991-05-22
DE69021214D1 (de)	1995-08-31
SG54210A1 (en)	1998-11-16
EP0502092A1 (de)	1992-09-09
PL166506B1 (pl)	1995-05-31
SE8903914D0 (sv)	1989-11-22
CA2071518C (en)	2002-11-12
HRP920632A2 (en)	1995-04-30
KR0179042B1 (ko)	1999-03-20
IS3644A7 (is)	1991-05-23
RU2134104C1 (ru)	1999-08-10
AU643021B2 (en)	1993-11-04
JPH05501705A (ja)	1993-04-02
EG19642A (en)	1995-08-30
ATE125445T1 (de)	1995-08-15
NO922004D0 (no)	1992-05-21
IL96415A (en)	1995-11-27
UA37196C2 (uk)	2001-05-15
HU9201700D0 (en)	1992-08-28
HU216836B (hu)	1999-09-28
HK51897A (en)	1997-05-02
IL96415A0 (en)	1991-08-16
FI922325A (fi)	1992-05-21
FI922325A0 (fi)	1992-05-21
YU48583B (sh)	1998-12-23
LTIP1751A (en)	1995-07-25
IE74854B1 (en)	1997-08-13
TW250435B (de)	1995-07-01
DE69021214T2 (de)	1996-01-04
LV10183B (en)	1995-08-20
ZA908777B (en)	1991-07-31
SA90110123B1 (ar)	1999-06-06
PL287844A1 (en)	1991-12-02
HUT60630A (en)	1992-10-28
NZ235807A (en)	1993-02-25
JP3145111B2 (ja)	2001-03-12

Publication	Publication Date	Title
NO304010B1 (no)	1998-10-12	FremgangsmÕte for fremstilling av en pelletformulering for bruk i behandlingen av inflammatoriske tarmsykdommer
US5643602A (en)	1997-07-01	Oral composition for the treatment of inflammatory bowel disease
JP3194974B2 (ja)	2001-08-06	標的制御釈放薬剤
JP4088413B2 (ja)	2008-05-21	腸管を処置・治療するペレット製剤
CA2683407C (en)	2016-09-20	Pharmaceutical cyclosporin compositions
CA1302262C (en)	1992-06-02	Pharmaceutical composition containing flutiasone propionate
EP0040590A2 (de)	1981-11-25	Pharmazeutische Zubereitung mit verbesserten Freisetzungseigenschaften
CZ281792B6 (cs)	1997-01-15	Orálně podávatelná farmaceutická dávkovací forma pro selektivní podávání léčiva do střev
EP1315481A1 (de)	2003-06-04	Arzneimittel zur behandlung von darmerkrankungen
JP3469926B2 (ja)	2003-11-25	大腸内放出型医薬製剤用粒状物
CA2579732C (en)	2014-08-12	Tablets with site time-controlled gastrointestinal release of active ingredient
EP0956006A1 (de)	1999-11-17	Verabreichung schwach saurer arzneistoffe an den kolon
EP1100481B1 (de)	2005-05-25	Pharmazeutische zusammensetzung enthaltend beclomethason-dipropionat zur behandlung entzündlicher darmerkrankungen
JP5371189B2 (ja)	2013-12-18	炎症性腸疾患の治療のためのシクレソニドの使用
WO1994007503A1 (en)	1994-04-14	Enteric preparations

Legal Events

Date	Code	Title	Description
2010-12-27	MK1K	Patent expired